|
Lawrence Bruder, President & Chief
Executive Officer
Maura O. Kahn, Vice President, Business Development and Marketing
David Opie, Ph.D., Vice President, Research and Development
Lawrence Bruder, President & CEO,
brings over 25 years of leadership and operational experience in large and
small life science companies, including Becton Dickinson, Applied Biosystems,
Leica, Olympus, and Guava Technologies. Most recently he was President and
CEO of venture-backed Guava Technologies, which was sold to Millipore Biosciences
in 2009. Most of his experience prior to Guava was at Becton Dickinson, where
he held a number of significant positions over a 10-year period. His responsibilities
in both companies included the clinical and regulatory aspects of 510(k)
submittals to the FDA for medical devices, significant commercial interaction
with pharmaceutical companies, and high level business development transactional
activity; all of these being a critical part of Noxilizer’s needs.
Mr. Bruder holds a BS from Rochester Institute of Technology and Master of
Management in Marketing & Economics from the Kellogg Graduate School
at Northwestern University.
Maura O. Kahn, Vice President, Business Development and Marketing, has 20 years of health care experience. Most recently, Maura was Senior Director of Marketing at MedImmune, responsible for developing and executing the marketing strategy and plan for Synagis. This franchise represents over 80% of total revenue for the company. Maura spent nine years at Eli Lilly in US Diabetes Marketing, Sales Management, Business Development and Global New Product Planning. She was a member of the US Humalog launch team, led the US launch of the Humulin/Humalog Pen and initiated the first ever direct-to-consumer campaign at Lilly. She was a member of the deal teams in Lilly’s successful negotiations with Takeda for Actos and Amylin for Byetta. She began her career at Targeted Communications and The RTC Group. Her clients included political candidates, trade associations and Fortune 500 companies. Ms. Kahn received her B.A. from Saint Mary’s College in Indiana and her M.B.A. from Indiana University.
David Opie, Ph.D., Vice President, Research and Development,
has extensive medical device development experience with both start-ups and industry leaders, including Johnson & Johnson and Cook Medical. He has employed a thorough knowledge of Good Laboratory Practices, Good Manufacturing Practices, and design control and product development procedures. He has experience with cardiovascular and urological implants as well as and drug delivery market segments. Dr. Opie holds a Ph.D. and an M.S. in Physics from the College of William and Mary, and a B.A. in Physics from the University of Delaware.
|
